CANbridge Pharmaceuticals Inc. (1228) Stock Statistics & Valuation Metrics

CANbridge Pharmaceuticals Inc. has a market cap or net worth of HK$1.23B. The enterprise value is HK$1.45B.

CANbridge Pharmaceuticals Inc. has 597,723,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

CANbridge Pharmaceuticals Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 32.86%.

The current PE Ratio of CANbridge Pharmaceuticals Inc. is ―. CANbridge Pharmaceuticals Inc.’s PEG ratio is -0.74.

In the last 12 months, CANbridge Pharmaceuticals Inc. had revenue of 49.98M and earned 14.82M in profits. Earnings per share was 0.03.

In the last 12 months, operating cash flow was -111.98M and capital expenditures -42.00K, giving a free cash flow of -112.02M billion.

CANbridge Pharmaceuticals Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

CANbridge Pharmaceuticals Inc. upcoming earnings date is Apr 1, 2027, Before Open (Not Confirmed).

CANbridge Pharmaceuticals Inc. as a current ratio of 0.24, with Debt / Equity ratio of -14.70%

In the past 12 months, CANbridge Pharmaceuticals Inc. has paid 0.00 in taxes.

CANbridge Pharmaceuticals Inc. EV to EBITDA ratio is -12.66, with an EV/FCF ratio of -26.17.

CANbridge Pharmaceuticals Inc. has HK$88.10M in cash and marketable securities with HK$28.81M in debt, giving a net cash position of HK$59.29M billion.

Gross margin is 71.47%, with operating margin of -185.46%, and net profit margin of 29.65%.

The average price target for CANbridge Pharmaceuticals Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―